- Home
- NMCO vs HUMA Comparison
NMCO vs HUMA Comparison
Compare NMCO & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | HUMA |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 236.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMCO | HUMA |
|---|---|---|
| Price | $10.21 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 207.6K | ★ 4.2M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $698.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $1.04 |
| 52 Week High | $11.64 | $5.66 |
Technical Indicators
Market Signals| Indicator | NMCO | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 37.60 |
| Support Level | $10.16 | $1.04 |
| Resistance Level | $10.78 | $1.17 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.68 | 16.67 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.